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ABSTRACT 24 
In this study, a Quality by Design (QbD) approach was used to identify the effect of formulation 25 
parameters in a twin screw wet extrusion granulation process for the manufacturing of 26 
ibuprofen (IBU) granules with increased dissolution rates. A fractional factorial Design of 27 
Experiment (DoE) was used to investigate the effect of the excipient composition, binder 28 
amount and liquid to solid (L/S) ratio (independent variables) on drug dissolution rates, median 29 
particle size diameter and specific surface area (dependent variables). The intra-granular 30 
addition of the binder in inorganic/polymer blends processed with ethanol as granulating 31 
liquids facilitated the formation of granules at various particle sizes.  DoE regression analysis 32 
showed that all formulation parameters affect the dependent variables significantly.  The 33 
enhanced dissolution rates were attributed not only to the IBU particle size reduction and 34 
adsorption in the porous inorganic network but also to the high specific surface area of the 35 
produced granules. Dynamic vapour sorption showed increased water absorption for granules 36 
with small particle size distribution and high specific surface area.  37 
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1. Introduction 57 
In the recent years twin–screw extrusion granulation (TSG) has attracted significant interest 58 
for the development of a variety of oral solid dosage forms such as granules, tablets or capsules 59 
in a continuous manufacturing manner. TSG approaches have been introduced as an alternative 60 
approach for the passage from batch processing to continuous manufacturing in the 61 
pharmaceutical industry. Although there are several reported studies, extrusion granulation is 62 
still in its infancy and further work is required to fully understand the technology (Schimdt et 63 
al., 2016).  In a recent study, Thompson et al highlighted the influence of various processing 64 
and formulation parameters on the granulation process. According to Thompson et al., and 65 
Djuric et al., scaling up of extrusion granulation is not a straightforward exercise and the 66 
mechanisms within the process need to be better understood (Thompson, 2015; Djuric et al., 67 
2009).  68 
The two major extrusion granulation approaches are a) wet granulation where the 69 
granulating liquid, with or without the addition of binders, is pumped into the screw zones and 70 
b) hot melt granulation which uses a molten binder to effectively bind the drug and the 71 
polymers (Weatherley et al., 2013).  Both process can effectively manufacture high quality 72 
granules for immediate or sustained drug release, however, both processes also present a 73 
number of drawbacks. For example, wet granulation requires a drying step for water removal 74 
that is time consuming while hot granulation uses relatively high barrel temperatures varying 75 
from 60-100oC.  76 
An in-depth study was presented by Vercruysse et al., using a six-segmented fluid bed dryer 77 
of the ConsiGma™-25 system comprising of a continuous twin screw granulation and drying 78 
system (Vercruysse et al., 2015a).  By running the system for 1 h the authors evaluated the 79 
effect of process outcomes, granule properties and tablet quality attributes. The torque and 80 
barrel wall temperatures were stabilized after 30 min performance while the tablet properties 81 
were adequate when comparing two ConsiGma systems (-1 and -25). Other studies have 82 
highlighted the impact of screw configuration on the particle size distribution, where conveying 83 
elements produced wide multimodal size distributions, while kneading elements have found to 84 
narrow the size of agglomerates (Vercruysse et al., 2015b; Meng et al., 2016).  The delivery of 85 
the binder in the powder blend or in the granulating liquid has a tremendous effect on the 86 
obtained granule quality (Saleh et al., 2015; Batra et al., 2016). The incorporation of binders, 87 
which are blended in the powder mix, resulted in longer residence times and higher torque, but 88 
also produced narrower particle size distribution, spherical granules and better binder 89 
distribution. In contrast, Fonteyne et al. demonstrated that excellent binder distribution can be 90 
obtained by both when the binder is added in the dry blend or when it is added within the 91 
granulation liquid (Fonteyne et al., 2014). In the case of melt granulation, low melting binders 92 
create stronger granules and the binder molecular weight appeared to have no effect in the 93 
process (Weatherley et al., 2013).  More recently the use of a foamed binder solution led to the 94 
formation of more uniform wetted mass and larger granule growth (Rocca et al., 2015; 95 
Thompson et al., 2012). 96 
Meier et al., (2016) showed that the feeder performance in conjunction to the screw design 97 
influences the granule quality for highly drug loaded formulations and the obtained granule 98 
particle size requires detailed knowledge of the feeding systems (Meier et al., 2016). The 99 
formulation composition is an aspect that clearly should be taken in account (Meier et al., 2015; 100 
Keen et al., 2015; Vanhoorne et al., 2016) where binary or ternary premix blends affect the 101 
granule quality as well as the drug dissolution rates. 102 
In order to understand the granulation process and the mechanisms involved during 103 
material processing, in – line and off – line process analytical tools (PAT) have been 104 
implemented to provide valuable insights (Fonteyne et al., 2016; Monteyne et al., 2016a,  105 
2016b; Kumar et al., 2014; Vercruysse et al., 2014; Chablani et al., 2011; Maniruzzaman et al., 106 
2015; Kumar et al., 2014). Near infrared (NIR) probes were used to measure the granules 107 
moisture content in comparison to Karl Fisher and loss of drying moisture measurements. In 108 
addition, NIR was used to understand the mixing and distribution of granulating liquid. The 109 
coupling of Raman mapping with twin – screw granulation provides information of the 110 
polymorph transitions and allows mapping of the drug distribution in the granular 111 
agglomerates. Similarly, the binder mixing efficiency and distribution was identified through 112 
hyperspectral coherent anti-Stokes Raman scattering (CARS) microscopy. The use of high-113 
speed camera enabled also the visualization of the particle size distribution and shape in real 114 
time.  115 
The purpose of the current study was to investigate the effect of formulation parameters 116 
such as excipient composition ratio, binder amount and L/S ratio on the granule formation of a 117 
water insoluble drug when processed with organic granulating liquids. Dry blends of inorganic 118 
excipients such as anhydrous dicalcium phosphate with a low molecular weight 119 
hydrohyxpropylmethyl cellulose (HPMC) grade were processed for first time with ethanolic 120 
granulating liquid.  121 
 122 
 123 
2. Materials and methods 124 
2.1 Materials 125 
Ibuprofen (IBU) was purchased from FarmaShino Pharmaceuticals Co. Ltd., (Nanjing, 126 
China) and dibasic calcium phosphate anhydrous (DCPA, Fujicalin®, DCPA) was kindly 127 
donated by Fuji Chemical Industries Co., Ltd. (Japan). Hydroxypropyl methylcellulose based 128 
polymer Pharmacoat 603 (HPMC) was kindly donated by Shin Etsu, Japan. Polyethylyne 129 
glycole 2000 (PEG) and ethanol (95%, 190 proof) were purchased from Sigma Aldrich 130 
(Gillingham, UK). All solvents used were of analytical grade and used as received. 131 
2.2 Twin screw granulation and DOE analysis 132 
Extrusion granulation studies were conducted using a twin-screw extruder (EuroLab 133 
16, Thermo Fisher, Duisburg, Germany) with a length/diameter (L/D) ratio of 40). A 134 
configuration with three kneading zones at 30o/40o /60o, 60o and 90o angles respectively was 135 
used for all the granulation trials. The IBU formulations were thoroughly mixed in a Turbula 136 
(TF2, Basel, Switzerland) mixer of 1 Kg batches for 10 min each, prior to the extrusion process. 137 
During granulation, dry blends of the drug, polymer, inorganic carrier and the binder PEG were 138 
fed into the extruder with a volumetric feeder (Brabender, Duisburg, Germany) at 1 kg/h feed 139 
rate while the screw rate was set at 100 rpm under ambient temperature.  A peristaltic pump, 140 
plunged in close proximity to the extruder’s feeding opening, supplied the granulating liquid 141 
(ethanol) at a constant rate. The “as made” extruded granules were dried in an oven (Memmert 142 
UF30, UK) at 30oC for 2h then further micronized through a cutter mill (Retsch, Germany) 143 
with a 250 µm fitted mesh.  144 
For the QbD approach a Design of Experiment (DoE) was introduced by using Fusion 145 
One software (DoE Fusion OneTM, California, USA). A response surface fractional factorial 146 
design (23+3=11) in randomized order with three centre points was designed with three 147 
independent and three dependant variables. The drug loading was kept constant (40%) where 148 
the DCPA/Polymer ratio (0.33 – 2.0), binder amount (5 – 12%) and L/S ratio (0.25 – 4.0) were 149 
set as independent variable. The drug release rate, the median particle size distribution (D50) 150 
and specific surface area (SSA) were defined as the dependant variables. 151 
 152 
2.3 Particle size analysis 153 
The particle size distribution of the extruded granules was determined using a 154 
Mastersizer 2000 laser diffraction analyser (Malvern Instruments, UK) with a dry powder 155 
sample dispersion accessory (Scirocco 2000). Samples were processed with a pressure at 0.5 156 
bars and a vibration feed rate of 50% in triplicate. The software analysis provided the d(10) 157 
d(50) and d(90) granular particle size values which are the geometric median particle size 158 
particle diameters at 10 and 90% of the cumulative volume distribution, respectively.  159 
 160 
2.4 Scanning electron microscopy (SEM) 161 
SEM images of the extruded IBU granules were captured using a cold-cathode field-162 
emission gun scanning electron microscope (Hitachi SU8030 FEG-SEM, Tokyo, Japan) with 163 
30 mm2 Ultra-Dry window and Noran 7 software. The samples were glued using adhesive 164 
carbon tape on sample tabs and coated with carbon (Edwards 306 high vacuum carbon 165 
evaporation) prior to the analysis. The accelerating voltage was set at 8 kV.  166 
 167 
2.5 X-ray powder diffraction (XRPD) 168 
XRPD was used to determine the solid state of bulk materials, physical mixtures and 169 
extruded granules using a Bruker D8 Advance (Karlsruhe, Germany) in theta-theta mode. For 170 
the study purposes a Cu anode at 40kV and 40Ma, parallel beam Goebel mirror, 0.2 mm exit 171 
slit, LynxEye Position Sensitive Detector with 3° opening (LynxIris at 6.5 mm) and sample 172 
rotation at 15 rpm were used. Each sample was scanned from 2 to 60° 2 with a step size of 173 
0.02° 2 and a counting time of 0.1 seconds per step; 176 channels active on the PSD making 174 
a total counting time of 35.2 seconds per step. The positions of the diffraction peaks for both 175 
the bulk, physical mixture and granulated products were identified using EVA phase analysis 176 
software (Bruker, Karlsruhe, Germany). TOPAS V4.2 structural analysis software (Bruker, 177 
Karlsruhe, Germany), was utilized to estimate the amount of amorphous content present in the 178 
granules. Crystal structural data of for Ibuprofen was taken from the Cambridge structural 179 
database (CSD) (REFCODE: JEKNOC10) and used as a standard alongside our granules. 180 
TOPAS scales the peaks to the standard and redistributes the rest which allows us to estimate 181 
the percentage amount of amorphous material present in the sample (Freer et al., 1993).  182 
 183 
2.6 Differential scanning calorimetry (DSC) study 184 
A Mettler-Toledo 823e (Greifensee, Switzerland) differential scanning calorimeter 185 
(DSC) was used to conduct thermal analysis of the bulk materials, physical mixtures and 186 
extruded granules. Typical samples of 3-5 mg were placed in sealed aluminium pans with 187 
pierced lids.  The samples were heated at 10°C/min from 0°C to 220°C under dry nitrogen 188 
atmosphere and reheated at the same heating rate. 189 
2.7 Dynamic vapour sorption (DVS) analysis 190 
Moisture sorption and desorption of the IBU loaded granules were determined via an automated 191 
gravimetric dynamic vapour sorption (DVS) analyser, Advantage-1 (Surface Measurements 192 
Systems Ltd, UK). All samples were equilibrated at 0% RH for 5 min to record the dry and 193 
reference mass prior to the exposition of the samples to the following relative humidity (% RH) 194 
profile: 0 to 100% in 20% steps and the reverse for desorption at 25.0±0.1°C and 40±0.1°C. At 195 
each stage, prior to the change of the humidity, the sample mass allowed to reach equilibrium 196 
defined as dm/dt=0.002 mg/min over 10 min, before the RH was changed. A total gas flow 200 197 
sccm was maintained throughout the study. The amount of water uptake was calculated as 198 
percentage of weight change compared to the dry initial mass. 199 
 200 
2.8 In vitro dissolution study 201 
In vitro drug dissolution studies were carried out in 900 ml of both 0.1 M HCl (pH 1.2) 202 
and 0.2 M dihydrogen-sodium-orthophosphate (pH adjusted with NaOH to 6.8) for 2 hr using 203 
a Varian 705 DS dissolution paddle apparatus (Varian Inc. North Carolina, US) at 100 rpm. 204 
The dissolution bath and the vessels were equilibrated at 37 ± 0.5°C. Samples (5ml) were 205 
withdrawn at predetermined time intervals for HPLC assay. All dissolution studies were 206 
performed in triplicate. 207 
 208 
2.9 HPLC analysis  209 
 The drug release was determined by HPLC analysis using an Agilent Technologies 210 
system 1200 series with a HYCHROME S50DS2-4889 (5 µm x 150 mm x 4mm) column. The 211 
mobile phase consisted of acetonitrile/water/phosphoric acid (65/35/0.2 v/v) while the flow 212 
rate and the wavelength were set at 1.5 ml/min and 214 nm. The calibration curve plotted with 213 
concentrations varying from 10 µg /ml to 50 µg/ml and 20 µl injection volumes. The IBU 214 
retention times varied from 2.5 – 3.0 min.  215 
 216 
3. Results and discussion 217 
3.1 Evaluation of extrusion granulation process 218 
The QbD is well defined by regulatory authorities and involves “A systematic approach 219 
to development that begins with predefined objectives and emphasizes product and process 220 
understanding and process control, based on sound science and quality risk management”. 221 
However, we need to clarify that the current QbD approach is limited to the process 222 
understanding and mainly to the effect of the formulation parameters on the extrusion 223 
granulation. The objectives included the formation of IBU granules with increase dissolution 224 
rates, uniform particle size distribution and excellent granule flowability.  225 
One of the most important aspects in extrusion granulation is the appropriate selection 226 
of the drug carriers as different polymer grades (viscosity and substitution degree) are directly 227 
related to the quality of granules and the drug dissolution rates (Vanhoorne et al., 2016). 228 
Although HPMC grades with a higher molecular weight have been utilized for sustained release 229 
formulations before, in this study we used HPMC substitution type 2910 with a higher degree 230 
of hydroxypropyl substituents, which has a low molecular weight and low viscosity. Because 231 
HPMC is insoluble in primary alcohols, no swelling occurred and hence low torque values 232 
were observed. There is only one study by Djuric and Kleinebudde where inorganic excipients 233 
such as DCPA are used to study the scale up of wet granulation processing (Djuric and 234 
Kleinebudde, 2010).  However, the authors used a low-quality grade of DCPA (Di-CaFos) with 235 
high cohesiveness and poor flowability. In this study, we introduced a spray-dried DCPA grade 236 
with excellent flowing properties, spherical shape, high surface area and porosity. As described 237 
above, for the purposes of the study the screw configuration consisted of three kneading blocks 238 
where disks offset at different angles varying at 30o, 60o and 90o (Fig.1).  Previous work has 239 
shown that kneading elements narrow the particle size of the granules (Vercruysse et al., 2015b; 240 
Meng et al., 2016) and particularly the 90o configurations increase agglomeration resulting in 241 
fewer fines and small particles (Thompson and Sun, 2010).    242 
The various PEG binder amounts were blended intra-granularly with the dry premix 243 
without being dissolved in the ethanolic granulating liquid to facilitate narrower granule size 244 
distribution with spherical shape and thus better flowability. In addition, DCPA has shown 245 
better granulating performance when processed with organic solvents. PEG was chosen as the 246 
binder due to its low molecular weight. PEG is extremely hydrophilic and hydrophilic binders 247 
have been shown to affect binder – polymer interactions (e.g. HPMC) and allow for faster 248 
dissolution rates (Tan et al., 2014).  Finally, the screw speed and feed rate were kept constant 249 
at 100 rpm and 1Kg/h respectively, hence the process throughput, in order to reduce the number 250 
of granulation variables. There are contradictory reports related to the screw speed and 251 
throughput increase (Kumar et al., 2014; Vercruysse et al., 2012; Tan et al., 2011) on the 252 
obtained particle size distribution and the formation of large agglomerates.  Thus, the effect of 253 
processing parameters would require a completely separate study and further experimentation. 254 
For the same reasons the IBU amount was kept at 40% for all formulations throughout the 255 
granulation process. 256 
As shown in Table 1 the DoE the independent variables included the DCPA/Polymer 257 
ratio (A), the binder amount (B) and the liquid/solid (C) ratio on the granulation process while 258 
the drug dissolution rate, the median particle size (D50) and the specific surface area (SSA) 259 
were identified as the dependent variables.  The software regression analysis (Table S1, Suppl. 260 
Material) showed that all independent variables have a significant effect on IBU dissolution 261 
rates (<0.05).  A two – way interaction between A/B, A/C and B/C showed also significant 262 
effect on dissolution suggesting a complex granulation process. These results are quite different 263 
to a similar study conducted by Maniruzzaman et al., where deionized water was used as 264 
granulating liquid and only the excipients ratio influenced the drug dissolution rates. Similarly, 265 
DCPA/HPMC, PEG amount and L/S have a significant effect on the granule particle size 266 
distribution (p<0.05). The latter is in good agreement with other extrusion granulation studies 267 
(Maniruzzaman et al., 2015; Dhenge et al., 2012). Finally, the granule specific surface area was 268 
affected significantly by the DCPA/Polymer ratio and the binder (PEG %) amounts.  269 
The contour plots in Fig. 2 show the response surface plots for the three dependent 270 
variables. The implementation and analysis of a response surface fractional factorial DoE with 271 
a reduced number of runs helped to identify the effects of the selected independent variables 272 
and identify those settings for granules of optimized quality.  273 
 274 
3.2 Particle morphology and distribution 275 
SEM analysis investigated the size and the morphology of the bulk materials and 276 
obtained granules.  Fig. 3 shows needle shaped crystal morphology for bulk unprocessed IBU 277 
while all extruded formulations appear as granular agglomerates with almost spherical shape. 278 
For some extruded formulations, SEM images show the presence of minuscule particles 279 
varying for 10 – 50 m. Furthermore, no drug crystals can be seen in the granules suggesting 280 
adsorption in the porous DCPA network (104 m2/g) and consequently particle size reduction 281 
of the drug substance through the granulation process. The average particle size of all extruded 282 
formulations (except F6) is much smaller compered to bulk IBU which supports this 283 
assumption.  It is likely that IBU was partly dissolved by ethanol which facilitated its particle 284 
size reduction. 285 
Additional investigations were conducted by using laser diffraction analysis to identify 286 
the particle size distribution of the various granules. As shown in Fig. 4 several of the 287 
granulated batches presented monomodal distribution while for most formulations the size 288 
distribution is bimodal. A careful observation of the laser diffraction analysis shows that 289 
bimodal distributions are related to either an increased amount of fine or large agglomerates. 290 
Table 1 shows a wide variation for the d(50) particle size diameter of all DOE experiments 291 
ranging from 188.0 – 1033m. The smaller particle size distributions correspond to higher SSA 292 
values, which can affect the granule hydration and consequently the IBU dissolution profiles. 293 
Furthermore, from Table 1 it can be observed that monomodal particle size distributions are 294 
affected by the DCPA/polymer (1:1) and binder amounts (8-12%).  As shown in Table S2 295 
(Suppl. Material) most of the granulated formulations presented excellent flowability which 296 
was attributed to the presence of DCPA and the obtained quality of the granules (Dhenge et al., 297 
2012).  298 
 299 
3.3 X-ray powder diffraction (XRPD) 300 
X-ray analysis of the bulk materials and extruded granules was carried out to investigate 301 
the physical state of IBU during processing. Fig. 5 (inset) shows distinct intensity peaks 302 
corresponding to IBU at 6.03o, 12.09o, 16.48o, 17.55o, 18.75o, 20.02o, 22.13o, 24.47o, 24.99o 2θ 303 
position and PEG at 19.01o and 23.49o 2θ position, respectively (data not shown). The 304 
comparison of the physical mixtures and extruded granules diffractograms in Fig.  5 showed a 305 
decrease on the intensity of the diffractograms for all formulations.  This indicates that a small 306 
fraction of IBU transformed from crystalline to amorphous during the granulation process. In 307 
order to obtain and identify the amount of amorphous content present, our data was fitted to a 308 
standard diffractogram taken from the Cambridge Structural Database (CSD). The amorphous 309 
content was then calculated from the redistributed amount which are not attributed to the 310 
crystalline material. This amorphous amount was found to be <5%. The usage of ethanol as 311 
granulating liquid and the application of high shear mixing due to the three zones of kneading 312 
elements facilitated the formation of a small amorphous IBU fraction. This is not uncommon 313 
and was also observed when aqueous granulating liquid or melt granulation were used for 314 
processing of IBU (Thompson, 2015). Extruded granules were further placed under accelerated 315 
stability conditions for six months and as expected, changes on IBU physical state were 316 
observed. As shown in Fig. S1 (Suppl. Material) a slight recrystallization of the amorphous 317 
fraction occurred at the end of the stability period.  It has also been previously reported that 318 
IBU’s mobility in the presence of PEG (Zhu et al., 2010) affects the drug physical state. 319 
 320 
 321 
 322 
3.4 DSC analysis 323 
DSC thermal analysis was conducted to further investigate the IBU physical state in the 324 
extruded granules in comparison to the bulk substance.  DSC scans were carried out for the 325 
bulk materials as well.  Fig. 6a illustrates the thermal melting transitions of bulk PEG and IBU 326 
with endothermic peaks at 62.05oC (H = 168.99 J/g) and 77.79oC (H = 92.42 J/g) 327 
respectively. Due to its amorphous nature HPMC presented a glass transition peak at 152.69oC 328 
while no thermal event was detected for DCPA. Fig. 6b shows the thermal events for the 329 
physical mixtures where PEG presented decreased melting endotherms varying from 59.3 – 330 
63.8oC while for IBU only negligible shifts at 77.5 – 78.5oC could be observed with melting 331 
peaks appeared broad. Further melting endotherm depression can be seen for the granulated 332 
formulations with PEG melting endotherms varying from 40.0 – 63.5oC and IBU from 69.5 – 333 
75.3oC, respectively.  334 
In both cases the thermal shifts are attributed to the PEG solubilizing capacity on IBU, 335 
which has been demonstrated in hot melt granulation studies.  Weatherley et al., observed 336 
stronger depression of both PEG and IBU melting endotherms in melted granules due to the 337 
solubilisation of IBU in the melted polymer (Weatherley et al., 2013). As we didn't apply any 338 
thermal processing for the current extrusion granulation the depression of the melting 339 
endotherms is also attributed to a combination of factors such as a) the particle size reduction 340 
caused by the kneading elements (Niazi, 2007)  and b) PEG reach domains in the granules due 341 
to the excellent mixing of the extrusion processing.   342 
 343 
3.5 DVS analysis 344 
The effect of controlled moisture on the physical solid state stability of the IBU granules 345 
manufactured via twin screw granulation process was studied using a DVS machine. The 346 
moisture absorption and desorption profiles of the manufactured granules assessed and 347 
monitored are depicted in Fig. 7.  For this study, it is assumed that the amount of water up-348 
taken by various granules can be correlated to its solid-state stability via the dynamic vapour 349 
sorption analysis.  The presence of hydrophilic components such as HPMC and PEG along 350 
with the inorganic DCPA, which promotes disintegration when used in oral solid dosage forms, 351 
may lead to an increased amount of water absorbed. As can be seen in Fig. 7, the vapour 352 
sorption isotherms indicates increased amount of water uptake upon increasing the relative 353 
humidity (RH) at two different conditions (ambient and 40oC). All formulations presented a 354 
mass increase from 1.1 – 3.0% at 60% RH at both 25oC and 40oC temperature settings. After 355 
60% RH the water sorption accelerated and the mass of the granules was further increased up 356 
to 6 – 7.0% at 100% RH for all three granules batches. As expected the desorption segments 357 
of F2, F8 and F9 exhibited a reversible process projected by the event of a steady water loss. 358 
All three batches showed similar DVS profiles regardless the difference in formulation 359 
compositions and the changes in mass at any relative humidity values higher than 80% RH, 360 
dropped significantly.   361 
The increase water sorption for the three granule batches was initially attributed to the 362 
composition of the formulations, which contain high amounts of hydrophilic carriers such as 363 
HPMC and PEG.  However, as it can be seen in Fig. 7(d), unlike other two formulations (F8 364 
and F9), F2 showed temperature independent mass gain as a function of water uptake. In both 365 
ambient and 40oC, F2 presented a significant mass gain when the relative humility reached 366 
100% RH. By examining the values of the dependent variables in Table 1 for the three batches 367 
carefully, it is noticed that F2 has a significant smaller particle size and higher SSA compared 368 
to the other two. Thus, the increased water sorption for F2 can be attributed to the impact of 369 
the physical properties such as particle size and SSA.   370 
 371 
3.6 In vitro dissolution studies 372 
One of the main targets of the extrusion granulation process was to enhance the 373 
dissolution rates of the water insoluble IBU. DCPA facilitates granule disintegration due to the 374 
rapid water uptake and HPMC has been reported to increase dissolution rates due to its 375 
hydrophilic nature.  Fig. 8 shows the dissolution profiles of high IBU loaded granules (40% 376 
w/w) for extruded formulations with the highest dissolution rates in comparison to bulk 377 
substance in acidic medium (pH1.2).  As it can be seen dissolution rates varied from 65 – 80% 378 
after 120min for the extruded granules while only 10% of bulk IBU was dissolved at the same 379 
time. As mentioned above all independent parameters have a significant effect on the granule 380 
dissolution rates. However, for the formulations with the best dissolution performance 381 
independent variables varied from 0.33 – 1.0 DCPA/HPMC ratios, 5 – 8% PEG amounts and 382 
0.25 – 0.3 L/S ratios. Since X-ray analysis showed a small amorphous fraction of IBU in the 383 
granules the increase dissolution rates were attributed to the drug adsorption in the inorganic 384 
porous network and the subsequent particle size reduction mentioned above.  In addition, faster 385 
dissolution rates were observed for granulated formulations with high specific surface area 386 
(>0.100m2/g), which is directly related to granule porosity.  The phenomenon is not uncommon 387 
and dissolution properties have found to be significantly affected by porosity changes of the 388 
prepared granules (Weatherley et al., 2013; Le et al., 2011) which can result in faster hydration 389 
rates and water sorption. This is in good agreement with the DVS analysis which showed higher 390 
water sorption for granules with high surface area and small particle size.  The accelerated 391 
stability batches (Fig. S2, Suppl. Material) presented similar dissolution profiles after six 392 
months without any significant changes irrespectively of the IBU recrystallization as 393 
mentioned above. 394 
4. Conclusions 395 
A QbD study was designed to identify the effect of formulation independent variables 396 
such as DCPA/Polymer ratio, binder concentration and L/S ratio on the dissolution rate, median 397 
particle size and specific surface area (dependent variables) of wet extruded IBU granules.  The 398 
DoE integration revealed that each dependent variable was significantly affected by the 399 
formulation parameters.  Physicochemical characterizations showed that IBU crystallinity was 400 
slightly affected and a small fraction turned to amorphous state, despite the use of ethanolic 401 
granulating liquid. The extruded granules showed uniform particle size distribution, excellent 402 
flowability and fast dissolution rates in acidic media due to IBU particles size reduction, 403 
through the granulation process, the adsorption in the porous inorganic excipient and the high 404 
specific surface area of the obtained granules.    405 
 406 
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TABLE(S) 519 
Table 1: DoE of extrusion granulation with DCPA/Polymer ration, binder amount (%) and L/S 520 
ratio as independent variables and release (%), median particle size diameter D(50) and specific 521 
surface area (m2/g) as dependent variables 522 
 
Process independent variables Process dependent variables 
Run 
No. 
DCPA/Polymer 
ratio 
Binder  
(%) 
L/S ratio 
 
Release (T120min) 
 (%) 
D(50) 
(µm) 
SSA  
(m2/g) 
F1 2.0 8.0 0.25 72.86 245.1 0.085 
F2 1.0 8.0 0.30 80.25 188.0 0.107 
F3 0.33 8.0 0.30 75.17 403.9 0.047 
F4 2.0 5.0 0.40 67.38 289.6 0.095 
F5 2.0 12.0 0.30 67.12 262.7 0.068 
F6 1.0 8.0 0.40 68.75 1033.1 0.024 
F7 0.33 12.0 0.40 71.03 583.3 0.072 
F8 0.33 5.0 0.25 76.66 287.2 0.062 
F9 1.0 5.0 0.30 64.89 251.9  0.032 
F10 1.0 8.0 0.30 79.90  200.5 0.101 
F11 1.0 12.0 0.25 66.23 327.0 0.068 
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Figures caption list 542 
 543 
Fig. 1 Image of the twin – screw configuration used for the extrusion granulation process. 
Fig. 2 Response surface plots of IBU release, specific surface area and particle size 
distribution dependent variables 
Fig. 3 SEM images of a) bulk IBU, b) F2 granules  (DCPA/Polymer 1.0, Binder 8.0%,  L/S 
ratio 0.30) and c) F10 granules (DCPA/Polymer 1.0, Binder 8.0%,  L/S ratio 0.30) 
Fig. 4 Laser diffraction particle size analysis of various extruded granules F2 
(DCPA/Polymer 1.0, Binder 8.0%,  L/S ratio 0.30), F9 (DCPA/Polymer 1.0, Binder 
5.0%,  L/S ratio 0.30) and F11 (DCPA/Polymer 1.0, Binder 12.0%,  L/S ratio 0.25) 
Fig. 5 XRPD diffractograms of bulk IBU (inset), physical mixture (red) and extruded 
granules (purple). 
Fig. 6 DSC thermographs of a) bulk DCPA, HPMC, IBU and b) physical mixtures and 
extruded granules. 
Fig. 7 DVS analysis of water sorption and desorption of F2 (DCPA/Polymer 1.0, Binder 
8.0%, L/S ratio 0.30), F8 (DCPA/Polymer 0.33, Binder 5.0%,  L/S ratio 0.25) and 
F9 (DCPA/Polymer 1.0, Binder 5.0%,  L/S ratio 0.30) extruded granules. 
Fig. 8 In vitro dissolution studies of bulk IBU and extruded granules (n=3, 37oC, 100 rpm). 
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